CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The expressTEC project is focused on developing an advanced diagnostic test, expressPIK, to improve the identification of breast cancer patients eligible for the drug PIQRAY. By measuring mutation expression levels in tumor RNA, it aims to enhance treatment outcomes and patient adherence.
Over 600k annual new cases of breast cancer worldwide carry poor prognosis mutations in the gene PIK3CA, but since 2020 a targeted therapeutic option – PIQRAY (alpelisib) – became available, exclusively from Novartis.
However, due to the still unsatisfactory response rates, the uptake by doctors and the adherence by patients has been limited.
Eligibility is established at present by assessing the PIK3CA status in tumour DNA via companion diagnostic (CDx) tests (from Qiagen and Roche).
However, w…
EXPRESSTEC - INVESTIGAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, LDA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
